Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100 |
| |
| Authors: | Anastasia-Stefania Alexopoulos MD Andreas Andersen PhD Anders Meller Donatsky MD Amoolya Gowda MD John B. Buse MD |
| |
| Affiliation: | 1. Department of Medicine, Division of Endocrinology, Duke University School of Medicine, Duke University, Durham, North Carolina, USA;2. Novo Nordisk A/S, Søborg, Denmark;3. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA |
| |
| Abstract: | In the DEVOTE and SWITCH 2 trials, insulin degludec 100 units/mL (degludec) was superior to insulin glargine 100 units/mL (glargine U100) with respect to the rates of severe (DEVOTE; across trial) and overall symptomatic (SWITCH 2; during the maintenance period of the trial) hypoglycaemia in individuals with type 2 diabetes. In this post hoc analysis, data from 7635 individuals from DEVOTE and 720 individuals from SWITCH 2 were analysed by subgroups of diabetes duration at baseline (<10, ≥10–<15, ≥15–<20 and ≥20 years) using prespecified models from both trials. There was a trend towards lower rates of hypoglycaemia with degludec versus glargine U100 across all diabetes duration subgroups in both trials, with the difference being statistically significant in some subgroups in DEVOTE and SWITCH 2. Overall, however, no significant interaction was observed between diabetes duration and treatment (DEVOTE interaction, P = .496; SWITCH 2 interaction, P = .144). Therefore, in this post hoc analysis of DEVOTE and SWITCH 2, diabetes duration did not appear to affect the reduction in rates of hypoglycaemia observed with degludec compared with glargine U100. |
| |
| Keywords: | basal insulin hypoglycaemia type 2 diabetes |
|
|
